Stockreport

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CAL [Read more]